AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22105505 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 30
Study 20831989 — intervention group
Group type: EXPERIMENTAL
Intervention: Batroxobin (5 IU through intravenous drip once every alternate day for a total of six doses)
Number of subjects: 52
Study 20831989 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (control group)
Number of subjects: 52
Study 18410301 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with sexual arousal disorder (29 participants)
Number of subjects: 59
Study 18410301 — intervention group
Group type: COMPARATOR
Intervention: Women without sexual problems (30 participants)
Number of subjects: 59
Study 16309036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazol 400 mg + Clindamycin 100 mg for 6 days (K/C6D)
Number of subjects: 82
Study 16309036 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazol 800 mg + Clindamycin 100 mg for 3 days + placebo for 3 days (K/C3D)
Number of subjects: 82
Study 11868797 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/hydrochlorothiazide combination (80 mg valsartan o.d. for 4 weeks, then fixed combination if needed)
Number of subjects: 310
Study 11868797 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg o.d. for 4 weeks, then increased to 10 mg if needed)
Number of subjects: 310
Study 11868797 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (valsartan/hydrochlorothiazide and amlodipine)
Number of subjects: 310
Study 9728901 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined contraceptive pill (250 microg levonorgestrel plus 30 microg ethinyl estradiol) administered intravaginally, one tablet per week for 8 weeks
Number of subjects: 40
Study 9728901 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogen cream (0.625 mg conjugated equine estrogens) administered intravaginally, 1 gm at bedtime, three times in the first week, twice in the second week, and then once a week for the next 6 weeks
Number of subjects: 40
Study 7639971 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose didanosine (200 mg for bodyweight < 60 kg; 134 mg for bodyweight ≥ 60 kg)
Number of subjects: 426
Study 7639971 — intervention group
Group type: COMPARATOR
Intervention: High dose didanosine (750 mg for bodyweight ≥ 60 kg; 500 mg for bodyweight < 60 kg)
Number of subjects: 426
Study 7639971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both low and high dose didanosine
Number of subjects: 426
Study 2768496 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPI under standard conditions
Number of subjects: 40
Study 2768496 — intervention group
Group type: COMPARATOR
Intervention: Fake good response set (MMPI for job application)
Number of subjects: 40
Study 2768496 — intervention group
Group type: COMPARATOR
Intervention: Fake bad response set (qualify for psychotherapy)
Number of subjects: 40
Study 2768496 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion of raw scores to T scores
Number of subjects: 40
Study 951455 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 15
Study 951455 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15
Study 951455 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise on a treadmill at 40 degrees or 10 degrees C
Number of subjects: 15
Study 951455 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial studies (monozygotic twins)
Number of subjects: 15
Study 951455 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial studies (dizygotic twins)
Number of subjects: 15
Study 951455 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-sex siblings discordant for affective illness
Number of subjects: 15
Study 30668163 — intervention group
Group type: EXPERIMENTAL
Intervention: Complior
Number of subjects: 316
Study 30668163 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriograph
Number of subjects: 316
Study 28053896 — intervention group
Group type: EXPERIMENTAL
Intervention: Champignon extract 50 mg/day
Number of subjects: 80
Study 28053896 — intervention group
Group type: EXPERIMENTAL
Intervention: Champignon extract 500 mg/day
Number of subjects: 80
Study 28053896 — intervention group
Group type: EXPERIMENTAL
Intervention: Champignon extract 1000 mg/day
Number of subjects: 80
Study 28053896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25565656 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of intravenous hydrocortisone 2 hours prior to surgery
Number of subjects: 30
Study 25565656 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 23493410 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic CRT optimization (at implant, at 3 and 6 months)
Number of subjects: 199
Study 23493410 — intervention group
Group type: COMPARATOR
Intervention: Non-systematic CRT optimization (less than three times during the year)
Number of subjects: 199
Study 23493410 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic CRT optimization
Number of subjects: 199
Study 23493410 — intervention group
Group type: COMPARATOR
Intervention: Non-systematic CRT optimization
Number of subjects: 199
Study 21932302 — intervention group
Group type: EXPERIMENTAL
Intervention: preHD group
Number of subjects: 36
Study 21932302 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 19555590 — intervention group
Group type: EXPERIMENTAL
Intervention: HV training with cognitive behavioural approach (CBA)
Number of subjects: 4084
Study 19555590 — intervention group
Group type: EXPERIMENTAL
Intervention: HV training with person-centred approach (PCA)
Number of subjects: 4084
Study 19555590 — intervention group
Group type: EXPERIMENTAL
Intervention: HV training (combined intervention group)
Number of subjects: 4084
Study 19555590 — intervention group
Group type: COMPARATOR
Intervention: Control group (HV usual care)
Number of subjects: 4084
Study 19555590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (HV training)
Number of subjects: 4084
Study 17182977 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/day)
Number of subjects: 25
Study 17182977 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE‐140 (18 μg/kg/h i.v. for 6 h)
Number of subjects: 25
Study 17182977 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE‐140
Number of subjects: 25
Study 15333192 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT)
Number of subjects: 263
Study 15333192 — intervention group
Group type: COMPARATOR
Intervention: Central laboratory testing (CLT)
Number of subjects: 263
Study 11489570 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% twice a day
Number of subjects: 45
Study 11489570 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% twice a day and dorzolamide 2% 3 times a day
Number of subjects: 45
Study 11489570 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2% 3 times a day
Number of subjects: 45
Study 9682660 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA meal
Number of subjects: 30
Study 9682660 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-MUFA meal
Number of subjects: 30
Study 9682660 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-MUFA meal
Number of subjects: 30
Study 7973963 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral decubitus position
Number of subjects: 50
Study 7973963 — intervention group
Group type: COMPARATOR
Intervention: Standing position
Number of subjects: 50
Study 7973963 — intervention group
Group type: EXPERIMENTAL
Intervention: Both positions
Number of subjects: 50
Study 31548151 — intervention group
Group type: EXPERIMENTAL
Intervention: blepharitis eyelid cleanser (OCuSOFT® Lid Scrub® PLUS foam)
Number of subjects: 48
Study 31548151 — intervention group
Group type: EXPERIMENTAL
Intervention: diluted baby shampoo (10% Johnson's® No More Tears ®)
Number of subjects: 48
Study 31548151 — intervention group
Group type: EXPERIMENTAL
Intervention: tea-tree based face wash (dr.organic®)
Number of subjects: 48
Study 31548151 — intervention group
Group type: COMPARATOR
Intervention: Cooled boiled water (control)
Number of subjects: 48
Study 28784054 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion according to low-dose standard protocol
Number of subjects: 270
Study 28784054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Misoprostol 25 μg every 4 h
Number of subjects: 270
Study 27409466 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-OCT+ (Microscope-Integrated OCT)
Number of subjects: 14
Study 27409466 — intervention group
Group type: COMPARATOR
Intervention: MI-OCT- (without MI-OCT guidance)
Number of subjects: 14
Study 27409466 — intervention group
Group type: COMPARATOR
Intervention: MI-OCT- (initially without MI-OCT guidance)
Number of subjects: 14
Study 25173140 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 0
Study 25173140 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 0
Study 23043888 — intervention group
Group type: EXPERIMENTAL
Intervention: riluzole treatment for 8 weeks
Number of subjects: 14
Study 23043888 — intervention group
Group type: COMPARATOR
Intervention: healthy subjects (control group)
Number of subjects: 14
Study 20492632 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA cell autografts
Number of subjects: 26
Study 20492632 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 26
Study 18234290 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.67 mg/kg)
Number of subjects: 22
Study 18234290 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 22
Study 16827700 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphadoxine/pyrimethamine (SP), administered up to four times during pregnancy
Number of subjects: 2688
Study 16827700 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2688
Study 16827700 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphadoxine/pyrimethamine (SP)
Number of subjects: 2688
Study 16827700 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphadoxine/pyrimethamine (SP) among women who did not use a bednet
Number of subjects: 2688
Study 16827700 — intervention group
Group type: COMPARATOR
Intervention: placebo among women who did not use a bednet
Number of subjects: 2688
Study 14632864 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented (stent left for 1 week)
Number of subjects: 64
Study 14632864 — intervention group
Group type: COMPARATOR
Intervention: Unstented (no stent)
Number of subjects: 64
Study 10871145 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented LowDye tape
Number of subjects: 14
Study 10871145 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary felt orthotics
Number of subjects: 14
Study 10871145 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 9083952 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser photocoagulation
Number of subjects: 19
Study 9083952 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 19
Study 8451010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg to 2.5 mg, taken once a day for 8 weeks)
Number of subjects: 25
Study 3953366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride (0.5 mg)
Number of subjects: 7
Study 29887287 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral CBD
Number of subjects: 16
Study 29887287 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral THC
Number of subjects: 16
Study 29887287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 26848956 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping exercise at various heights and cadences (80, 90, 100, 110 steps-min-1; heights of 17, 25, 30, 34 cm)
Number of subjects: 28
Study 26848956 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptive equation for energy cost in METs
Number of subjects: 28
Study 25146960 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and counseling intervention to improve self-care in patients with HF
Number of subjects: 612
Study 25146960 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 612
Study 22508151 — intervention group
Group type: EXPERIMENTAL
Intervention: 57 μg/kg/day r-hGH
Number of subjects: 22
Study 22508151 — intervention group
Group type: COMPARATOR
Intervention: 35 μg/kg/day r-hGH
Number of subjects: 22
Study 19996196 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pirfenidone (1,800 mg/day)
Number of subjects: 275
Study 19996196 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pirfenidone (1,200 mg/day)
Number of subjects: 275
Study 19996196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 18789113 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytapheresis
Number of subjects: 0
Study 16125959 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 1g before skin incision and continuously 200mg/h
Number of subjects: 91
Study 16125959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 1,000,000 IU before skin incision and 250,000 IU/h
Number of subjects: 91
Study 16125959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 11898025 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin (0.15 mg/kg/day divided into two equal doses via intramuscular injection)
Number of subjects: 24
Study 11898025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11898025 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin
Number of subjects: 24
Study 10091821 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pulse pressure
Number of subjects: 6781
Study 10091821 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean arterial pressure
Number of subjects: 6781
Study 7772081 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol tablets 4 g/day
Number of subjects: 317
Study 7772081 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol tablets 16 g/day
Number of subjects: 317
Study 7772081 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol granules 4 g/day
Number of subjects: 317
Study 7772081 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol granules 16 g/day
Number of subjects: 317
Study 7772081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 2267478 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 h of bright light exposure in the morning
Number of subjects: 20
Study 2267478 — intervention group
Group type: EXPERIMENTAL
Intervention: Light restriction in the evening
Number of subjects: 20
Study 7438772 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily, increased to a maximum of 400 mg)
Number of subjects: 20
Study 7438772 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (same total dosage as twice-daily regimen, administered once daily)
Number of subjects: 20
Study 7438772 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during 4-week run-in period)
Number of subjects: 20
Study 31910903 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg once daily
Number of subjects: 56
Study 31910903 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 56
Study 31910903 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg once daily
Number of subjects: 56
Study 31910903 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 56
Study 31910903 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 56
Study 30991661 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise with moderate intensity
Number of subjects: 60
Study 30991661 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise with high intensity
Number of subjects: 60
Study 30991661 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic aerobic exercise with moderate intensity
Number of subjects: 60
Study 30991661 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic aerobic exercise with high intensity
Number of subjects: 60
Study 28076358 — intervention group
Group type: EXPERIMENTAL
Intervention: Congregate Housing First (CHF)
Number of subjects: 297
Study 28076358 — intervention group
Group type: EXPERIMENTAL
Intervention: Scattered Housing First (SHF)
Number of subjects: 297
Study 28076358 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 297
Study 25887324 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-Yoga intervention (8-week duration, biweekly one-hour classes via multipoint videoconferencing)
Number of subjects: 15
Study 25887324 — intervention group
Group type: COMPARATOR
Intervention: Educational control (information leaflets mailed with one phone call a week)
Number of subjects: 15
Study 24073411 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite cervical screening initiative
Number of subjects: 403
Study 24073411 — intervention group
Group type: COMPARATOR
Intervention: Usual care from the existing cervical screening program
Number of subjects: 403
Study 21544823 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewed enteric-coated acetylsalicylic acid (ECA)
Number of subjects: 0
Study 21544823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact or chewed nonenteric-coated buffered acetylsalicylic acid (NBA)
Number of subjects: 0
Study 21544823 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewed ECA
Number of subjects: 0
Study 21544823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact or chewed NBA
Number of subjects: 0
Study 19124530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber permanent pacing with rate-drop response programming (DDD/RDR)
Number of subjects: 34
Study 19124530 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ODO)
Number of subjects: 34
Study 17876251 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 66
Study 17876251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 66
Study 17876251 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Oxycodone and Ibuprofen
Number of subjects: 66
Study 17876251 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 66
Study 14706480 — intervention group
Group type: EXPERIMENTAL
Intervention: SMR training (12-15 Hz)
Number of subjects: 25
Study 14706480 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta1 training (15-18 Hz)
Number of subjects: 25
Study 14706480 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-neurofeedback)
Number of subjects: 25
Study 11254160 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler velocimetry of the umbilical artery
Number of subjects: 0
Study 9431267 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg acetylsalicylic acid (ASA)
Number of subjects: 10
Study 9431267 — intervention group
Group type: COMPARATOR
Intervention: No acetylsalicylic acid (ASA)
Number of subjects: 10
Study 8497169 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril (10-40 mg/d)
Number of subjects: 60
Study 8497169 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (25-100 mg/d)
Number of subjects: 60
Study 8497169 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil-retard (120-240 mg/d)
Number of subjects: 60
Study 8497169 — intervention group
Group type: EXPERIMENTAL
Intervention: alphametildopa (250 mg/8h to 3 g/d)
Number of subjects: 60
Study 3580510 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine formulations (10 mg single dose)
Number of subjects: 12
Study 3580510 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation of plasma profiles of nifedipine
Number of subjects: 12
Study 3580510 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods for bioequivalence evaluation
Number of subjects: 12
Study 31167421 — intervention group
Group type: EXPERIMENTAL
Intervention: Andalusian aged white wine (AWW)
Number of subjects: 38
Study 31167421 — intervention group
Group type: COMPARATOR
Intervention: gin
Number of subjects: 38
Study 28983803 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Astigmatism (IA)
Number of subjects: 206
Study 28983803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Residual Astigmatism (ORA)
Number of subjects: 206
Study 28983803 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal Astigmatism (ACA)
Number of subjects: 206
Study 28983803 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IA and ORA with axial length
Number of subjects: 206
Study 28983803 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IA and ORA with spherical equivalent refraction
Number of subjects: 206
Study 28983803 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IA and ORA with corneal astigmatism
Number of subjects: 206
Study 28983803 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of IA powers between genders
Number of subjects: 206
Study 25480874 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (5-FU/LV or capecitabine)
Number of subjects: 437
Study 25480874 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 437
Study 23323721 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication dispensing device
Number of subjects: 96
Study 21981853 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive repetitive transorbital alternating current stimulation (rtACS)
Number of subjects: 42
Study 21981853 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 42
Study 19799779 — intervention group
Group type: EXPERIMENTAL
Intervention: Community occupational therapy programme including 10 sessions occupational therapy at home
Number of subjects: 140
Study 19799779 — intervention group
Group type: COMPARATOR
Intervention: Community occupational therapy consultation based on information material of the Alzheimer Society
Number of subjects: 140
Study 19799779 — intervention group
Group type: EXPERIMENTAL
Intervention: Community occupational therapy programme
Number of subjects: 140
Study 16399302 — intervention group
Group type: EXPERIMENTAL
Intervention: Single aortic clamping (reduced aortic manipulation)
Number of subjects: 169
Study 16399302 — intervention group
Group type: COMPARATOR
Intervention: Multiple aortic clamping (traditional approach)
Number of subjects: 169
Study 16399302 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass surgery
Number of subjects: 169